QURE

+ Watchlist + Portfolio

uniQure N.V.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $48.76
52-Week Range: $8.73 – $71.50
Market Cap: $3.39B
P/E (TTM): —
EPS (TTM): -4.06
Dividend Yield: —

Advanced Metrics

Price/Book: 10.46
PEG Ratio: —
Return on Equity: -157.61%
Return on Assets: -15.72%
Gross Margin: 0.00%
Operating Margin: -872.23%
Profit Margin: 0.00%
Current Ratio: 10.01
Debt/Equity: 1.70
Total Debt: $552.17M
Free Cash Flow: $-77.58M
Revenue Growth: 11.00%
Earnings Growth: —
Enterprise Value: $3.12B

QURE Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$106.48M	$15.84M	$27.12M	$16.10M
Cost of Revenue	$3.34M	$13.63M	$18.33M	$1.69M
Gross Profit	$103.14M	$2.21M	$8.79M	$14.41M
Research & Development	$197.59M	$214.86M	$143.78M	$140.67M
Selling, General & Admin	$54.70M	$73.08M	$50.68M	$65.34M
Operating Expenses	$247.39M	$284.70M	$190.97M	$202.24M
Operating Income	-$144.25M	-$282.49M	-$182.18M	-$187.83M
EBITDA	-$108.02M	-$253.10M	-$160.75M	-$116.59M
Pretax Income	-$128.26M	-$306.56M	-$237.13M	-$193.34M
Income Tax	-$1.47M	$1.92M	$2.43M	$5.63M
Net Income	-$126.79M	-$308.48M	-$239.56M	-$198.97M
Diluted EPS	-2.71	-6.47	-4.92	-3.46
Diluted Shares	46.74M	47.67M	48.65M	57.50M

QURE Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$228.01M	$241.36M	$158.93M	$80.24M
Receivables	$102.38M	$4.19M	$5.88M	$5.86M
Inventory	$6.92M	$12.02M	$0.00	—
Current Assets	$476.77M	$651.85M	$390.29M	$655.99M
Total Assets	$704.96M	$831.69M	$556.54M	$824.91M
Current Liabilities	$75.92M	$73.67M	$40.05M	$62.92M
Long-Term Debt	$102.79M	$101.75M	$51.32M	$49.70M
Total Debt	$142.89M	$138.41M	$66.06M	$63.39M
Total Liabilities	$228.96M	$624.02M	$563.29M	$626.01M
Retained Earnings	-$581.93M	-$890.41M	-$1.13B	-$1.33B
Shareholders' Equity	$476.01M	$207.67M	-$6.75M	$198.90M
Working Capital	$400.86M	$578.18M	$350.24M	$593.07M

QURE Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$145.06M	-$145.93M	-$182.73M	-$177.96M
Capital Expenditure	-$17.69M	-$7.15M	-$11.69M	-$439.00K
Free Cash Flow	-$162.75M	-$153.08M	-$194.42M	-$178.40M
Depreciation & Amortisation	$8.54M	$11.90M	$12.64M	$14.76M
Stock-Based Compensation	$34.20M	$35.09M	$22.26M	$17.68M
Investing Cash Flow	-$182.73M	-$205.69M	$162.97M	-$321.62M
Financing Cash Flow	$1.45M	$362.72M	-$59.49M	$415.40M
Net Change in Cash	-$326.35M	$11.11M	-$79.25M	-$84.18M

QURE Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$5.26M	$3.70M	$5.57M	$3.56M	$5.84M
Cost of Revenue	$656.00K	$398.00K	$435.00K	$219.00K	$350.00K
Gross Profit	$4.61M	$3.30M	$5.13M	$3.34M	$5.49M
Research & Development	$35.38M	$34.37M	$34.78M	$29.18M	$33.96M
Selling, General & Admin	$13.50M	$19.44M	$21.49M	$20.07M	$17.37M
Operating Expenses	$47.49M	$52.79M	$56.63M	$47.61M	$50.17M
Operating Income	-$42.88M	-$49.49M	-$51.49M	-$44.27M	-$44.68M
EBITDA	-$18.07M	-$51.55M	-$23.46M	-$36.06M	-$59.95M
Pretax Income	-$37.29M	-$71.90M	-$41.00M	-$53.05M	-$79.22M
Income Tax	$425.00K	$8.63M	-$3.92M	$488.00K	$1.84M
Net Income	-$37.72M	-$80.53M	-$37.09M	-$53.53M	-$81.06M
Diluted EPS	-0.69	-1.38	—	-0.85	-1.22
Diluted Shares	54.81M	58.52M	—	62.74M	66.24M

QURE Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$253.78M	$597.06M	$80.24M	$139.99M	$413.03M
Receivables	$5.61M	$3.88M	$5.86M	$3.56M	$5.78M
Current Assets	$408.57M	$716.19M	$655.99M	$615.74M	$834.27M
Total Assets	$584.89M	$888.38M	$824.91M	$778.71M	$985.10M
Current Liabilities	$40.93M	$100.63M	$62.92M	$59.20M	$83.34M
Long-Term Debt	$51.84M	$51.88M	$49.70M	$49.94M	$50.15M
Total Debt	$66.70M	$66.16M	$63.39M	$63.32M	$62.83M
Total Liabilities	$588.89M	$659.64M	$626.01M	$629.36M	$661.05M
Retained Earnings	-$1.21B	-$1.29B	-$1.33B	-$1.38B	-$1.46B
Shareholders' Equity	-$4.00M	$228.75M	$198.90M	$149.34M	$324.05M
Working Capital	$367.64M	$615.56M	$593.07M	$556.55M	$750.92M

QURE Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$39.90M	-$16.40M	-$77.57M	-$38.24M	-$28.58M
Capital Expenditure	-$260.00K	—	-$119.00K	-$140.00K	-$472.00K
Free Cash Flow	-$40.16M	-$16.33M	-$77.69M	-$38.38M	-$29.05M
Depreciation & Amortisation	$3.63M	$3.63M	$2.97M	$2.96M	$4.91M
Stock-Based Compensation	$5.08M	$3.52M	$4.66M	$5.09M	$5.02M
Investing Cash Flow	$73.07M	$26.58M	-$441.37M	$98.56M	$53.26M
Financing Cash Flow	$44.00K	$332.24M	$2.45M	$550.00K	$249.12M
Net Change in Cash	$33.22M	$342.42M	-$516.49M	$60.87M	$273.80M

Market Snapshot

About

uniQure is a Netherlands-based gene therapy biotechnology company focused on developing treatments for patients with severe genetic diseases. The company has a leading hemophilia B gene therapy candidate and a pipeline targeting other rare disorders. uniQure combines proprietary adeno-associated virus (AAV) technology with clinical development expertise to advance potentially curative one-time treatments.